Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0CKSWS
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
CMG-901
|
|||||
| Synonyms |
CMG 901; CMG-901; CMG901; MRG005; Sonesitatug vedotin; AZD0901
Click to Show/Hide
|
|||||
| Organization |
Keymed Biosciences, Inc.; Shanghai Miracogen Inc.; Lepu Biopharma Co., Ltd.; AstraZeneca PLC
|
|||||
| Drug Status |
Phase 3
|
|||||
| Indication |
In total 5 Indication(s)
|
|||||
| Drug-to-Antibody Ratio |
Undisclosed
|
|||||
| Antibody Name |
Sonesitatug
|
Antibody Info | ||||
| Antigen Name |
Claudin-18.2 (CLDN18.2)
|
Antigen Info | ||||
| Payload Name |
Monomethyl auristatin E
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
Mc-Val-Cit-PABC
|
Linker Info | ||||
| Conjugate Type |
Random Cysteines
|
|||||
| Combination Type |
vedotin
|
|||||
| Special Approval(s) |
Breakthrough therapy(FDA); Breakthrough therapy(NMPA); Fast track(FDA); Orphan drug(FDA)
|
|||||
General Information of The Activity Data Related to This ADC
Identified from the Human Clinical Data
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Objective Response Rate (ORR) |
75.00% (Gastric/GEJ Cancer)
|
|||
| Patients Enrolled |
Patients with advanced malignant tumors.
|
||||
| Administration Dosage |
Day 1 in 3-week (Q3W) cycle 3.40 mg/kg.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT04805307 | Clinical Status | Phase 1 | ||
| Clinical Description | An open-label, phase 1, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics and antitumor activities of CMG901 in subjects with advanced unresectable or metastatic solid tumor. | ||||
References